netFormulary

Lancashire and South Cumbria
Formulary

2 Cardiovascular system

02-05-05-02 Angiotensin-II receptor antagonists

Angiotensin-II receptor antagonists reserved for use when ACE inhibitors are not tolerated.

Losartan

Formulary

Tablets 12.5mg, 25mg, 50mg, 100mg

First line

Candesartan

Formulary

Tablets 2mg, 4mg, 8mg, 16mg, 32mg

First line

Irbesartan

Formulary

Tablets 75mg, 150mg, 300mg

Sacubitril/valsartan Entresto^®

Formulary

film-coated tablets
24.3 mg sacubitril and 25.7 mg valsartan (as sacubitril valsartan sodium salt complex).
48.6 mg sacubitril and 51.4 mg valsartan (as sacubitril valsartan sodium salt complex).
97.2 mg sacubitril and 102.8 mg valsartan (as sacubitril valsartan sodium salt complex).

Entresto® tablets and granules contain sacubitril and valsartan in the form x/y where x and y are the strength in milligrams of sacubitril and valsartan respectively. Doses in BNF Publications are expressed as the total of both drug strengths.

For Entresto® tablets, the 24/26 mg, 49/51 mg, 72/78 mg, and 97/103 mg strengths are referred to as 50 mg, 100 mg, 150 mg, and 200 mg, respectively.

See BNF for more detail.

Ensure that all other ACE inhibitor and/or angiotensin receptor blocker therapy is stopped.

Initiation should be by the heart failure specialist team.

The specialist team must titrate, prescribe, and monitor until the patient is stabilised on an optimised dose (2-3 weeks on optimised dose).